Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary ...

Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.

Two Phase 3 multicenter trials of OCS-01 (OPTIREACH-enabled topical dexamethasone 15 mg/mL) missed 52-week BCVA and ≥15-letter gain endpoints, prompting abandonment of an FDA NDA for DME. Dosing ...

Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the internal mammary and medial supraclavicular lymph nodes reduces breast cancer ...

Please provide your email address to receive an email when new articles are posted on . The intervention reduced depression and anxiety and improved health-related quality of life at 6 months. Those ...

A former Ironman triathlete was stunned to learn that his vision problems were actually the first sign of stage 4 lung cancer. Dave Nitsche, 57, was initially given just 12 to 24 months to live – but ...

Months after revealing his stage 4 cancer diagnosis, former U.S. Sen. Ben Sasse is speaking out about an experimental therapy that could extend his life. Sasse, a Republican who represented Nebraska ...

Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the FDA, industry influence, and the agency’s ability to protect and promote public health.

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...